One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%. Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advan ...

Former President Joe Biden has been diagnosed with an "aggressive" form of prostate cancer that has spread to his bones. But ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

The objective of this study was to assess whether adding CAN-2409 in combination with the prodrug valacyclovir to standard of ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Researchers at UC San Diego, led by Professor Trey Ideker (right) are included in a $142 million initiative from ARPA-H with ...

Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on chromosomal instability, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase ...

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low ...

ILC accounts for 10–15% of breast cancers and often goes undetected. Learn about its characteristics, treatments, and future ...

The field of tumor immunology has highlighted the adeptness of tumor cells in evading the host's immune system. This insight has fueled interest in ...